title: Retreatment with purine analogs in patients with chronic lymphocytic leukemia.
abstract: We evaluated the efficacy and toxicity of retreatment with purine analogs (PA) in 62 patients with relapsed chronic lymphocytic leukemia. Median OS and PFS after retreatment were 60 and 26 months, respectively. By multivariate analysis, minimal residual disease status, ZAP-70 expression and age had independent predictive power in terms of OS. Toxicity was mainly neutropenia (21%) and infections (39%). Second malignancies were observed in 10 (16%) patients. Our results outline that retreatment with PA is remarkably effective in patients with relapsed CLL, but with a significant toxicity.
authors.affiliation: Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic, Barcelona, Spain. idlouhy@clinic.ub.es
authors.forename: Ivan
authors.initials: I
authors.lastname: Dlouhy
authors.forename: Gabriela
authors.initials: G
authors.lastname: Ghita
authors.forename: Tycho
authors.initials: T
authors.lastname: Baumann
authors.forename: Eva
authors.initials: E
authors.lastname: Gine
authors.forename: Neus
authors.initials: N
authors.lastname: Villamor
authors.forename: Maria
authors.initials: M
authors.lastname: Rozman
authors.forename: Alejandra
authors.initials: A
authors.lastname: Martinez-Trillos
authors.forename: Armando
authors.initials: A
authors.lastname: Lopez-Guillermo
authors.forename: Julio
authors.initials: J
authors.lastname: Delgado
mesh_terms: D000367:Age Factors; D000368:Aged; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications / Q000473:pathology; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018365:Neoplasm, Residual; D009503:Neutropenia / Q000150:complications / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D011687:Purines / Q000008:administration & dosage* / Q000009:adverse effects; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D016019:Survival Analysis; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000235:genetics / Q000378:metabolism
chemical_list: D011687:Purines; D051746:ZAP-70 Protein-Tyrosine Kinase